RECRUITMENT FOR CLINICAL STUDY

Hong Kong Integrated Oncology Centre is currently conducting a **Phase 3 clinical study, open-label, randomized trial in patients with advanced/metastatic NSCLC who have acquired resistance to immune checkpoint inhibitor plus platinum-based chemotherapy.**


If you are a patient with pathologically confirmed **Stage IV NSCLC and acquired resistance to immune checkpoint inhibitor therapy**, please contact us.

1. You will be screened for eligibility to participate in the trial.
2. Study medications, study required imaging and doctor consultation will befree of charge.
3. Participants should be aware of the objectives and potential risks of the trial.

STUDY DESIGN

You will be randomly assigned to one of the following treatment arms*

(2:1 RATIO)



*** The investigator will tell you which arm you will be in**

Study Number: ResQ201A-NSCLC

Study Title: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy.

This advertisement is approved by Research Ethical Committee, Hong Kong Oncology Study Group

FOR ENQUIRIES 3700 6888 info@hkioc.com.hk

HONG KONG INTEGRATED ONCOLOGY CENTRE
NF HEALTH